Microbix Biosystems Inc.

228 articles with Microbix Biosystems Inc.

• Microbix Reports Results for Q2 Fiscal 2020Timing of Product Shipments Affects Results

  5/14/2020

  Microbix Biosystems Inc., an award-winning life sciences innovator and exporter, reports results for its second quarter and first half of fiscal 2020 ended March 31, 2020, with the timing of product shipments to customers affecting Q2 results.

• Microbix Announces Quality Products Distribution AgreementAppointment of D.I.D. S.p.A. of Milan for Italy

  5/12/2020

  Microbix Biosystems Inc. (TSX: MBX, Microbix®), an award-winning life sciences innovator and exporter, announces the appointment of Diagnostic International Distribution S.p.A. of Milan (D.I.D.) as distributor of its Quality Assessment Products (QAPs™) for Italy. Under an agreement between the parties, D.I.D. has been appointed as distributor of Microbix’s quality assessment products (QAPs™) for Italy. As distributor, D.I.D. will provide

• Microbix COVID-19 QAPs Now Available for U.S. LabsRegistration Enables Immediate Usage of SARS-CoV-2 Controls by U.S. Clinical Labs

  5/7/2020

  Microbix Biosystems Inc., an award-winning life sciences innovator and exporter, is pleased to announce U.S. availability of its SARS-CoV-2 quality assessment products – FDA registration enabling immediate usage by U.S. clinical laboratories to evaluate performance, procedures, and workflow of tests that detect SARS-CoV-2 virus, the causative agent of COVID-19 disease.

• Microbix Begins Providing COVID-19 Test Quality Products

  5/6/2020

  Microbix Biosystems Inc., an award-winning life sciences innovator and exporter, announces that it has begun providing its REDx™FLOQ® SARS-CoV-2 swab-format and REDx™ SARS-CoV-2 vial format quality assessment products as controls to clinical laboratories in Canada.

• Microbix Announces Quality Products Distribution AgreementAppointment of Labquality Oy of Finland for 7 Countries

  4/27/2020

  Microbix Biosystems Inc., an award-winning life sciences innovator and exporter, announces the appointment of Labquality Oy as a distributor of its Quality Assessment Products in seven countries.

• Microbix Participating in COVID-19 Virtual ConferencePresentation and Panel Participation at Adelaide Capital Event on April 23  

  4/21/2020

  Microbix Biosystems Inc. (TSX: MBX, Microbix®), an award-winning life sciences innovator and exporter, announces that it will be participating in the “Virtual COVID & Healthcare Mini Conference” being hosted by Adelaide Capital on April 23 from 12:00-5:00 PM ET. The conference will showcase the contributions that Canadian companies are making to help fight the coronavirus pandemic. Microbix will be discussing its longstanding work

• Microbix Attains Health Canada Establishment LicensingEnables Immediate Usage of SARS-CoV-2 Controls by Clinical Labs across Canada

  4/21/2020

  Microbix Biosystems Inc. (TSX: MBX, Microbix®), a life sciences innovator and exporter, announces that it has attained medical devices establishment licensing from Health Canada, enabling the immediate usage of its quality assessment products (QAPs™) by clinical laboratories, including its QAPs to help ensure the accuracy of COVID-19 disease testing.

• Microbix & Oneworld Create COVID-19 Test Quality ProgramLaboratory External Quality Assessment, Proficiency Testing, & Accreditation

  4/9/2020

  Microbix Biosystems Inc. and Oneworld Accuracy announce a strategic collaboration to provide a global external quality assessment program to support clinically-effective COVID-19 testing.

• Microbix Announces Annual and Special Meeting Voting Results

  4/1/2020

  Microbix Biosystems Inc., a life sciences innovator making critical ingredients that enable the production of clinical diagnostics and creating medical devices that help ensure test accuracy, announces the voting results from the Annual and Special Meeting of Shareholders which was held on March 31, 2020.

• Microbix Creates Quality Assessment Product for COVID-19 TestsWhole-genome QMS Support Tool on COPAN® FLOQSwabs®

  3/30/2020

  Microbix Biosystems Inc. announces the creation, verification, and imminent commercial availability of a quality assessment product to help ensure the accuracy of COVID-19 disease testing..

• Microbix Annual General Meeting Process UpdateRemote Access to the AGM Provided to Avoid Physical Attendance

  3/25/2020

  Microbix Biosystems Inc., a life sciences innovator making critical ingredients that enable the production of clinical diagnostics and creating medical devices that help ensure test accuracy, provides an update about its Annual General Meeting.

• Microbix Announces Quality Products Distribution AgreementAppointment of Medical Supply Company of Ireland

  3/24/2020

  Microbix Biosystems Inc. announces the appointment of The Medical Supply Company of Ireland as a distributor.

• Microbix Announces Issuance of Stock OptionsUsing Shareholder-Approved Plan to Incentivize and Retain

  2/25/2020

  Microbix Biosystems Inc. (TSX: MBX, Microbix®), a life sciences innovator making critical ingredients that enable the production of clinical diagnostics and creating medical devices that help ensure test accuracy, announces the issuance of stock options under its shareholder-approved 2018 stock option plan (the “Stock Option Plan”), as part of its compensation programs to incentivize and retain its board of directors, executives, and managers.

• Microbix Reports Results for Q1 Fiscal 2020Positive Cash Flow from Operations Achieved

  2/13/2020

  Microbix Biosystems Inc. (TSX: MBX, Microbix®), a life sciences innovator making critical ingredients that enable the production of clinical diagnostics and creating medical devices that help ensure test accuracy, reports results for its first quarter of fiscal 2020 (“Q1”) ended December 31, 2019, with positive cash flow from operations (“CFO”) and seasonally weak sales.

• Microbix Completes Non-Brokered Private Placement of $2.3 million

  1/31/2020

  Microbix Biosystems Inc., a life sciences innovator making critical ingredients that enable the production of clinical diagnostics and creating medical devices that help ensure test accuracy, announces that it has completed a non-brokered private placement financing with gross proceeds of $2,355,000, by issuing an aggregate of 11,775,000 units at a price of $0.20 per Unit.

• Microbix Completes Non-Brokered Private Placement of $2.3 millionProceeds to Support Ongoing Sales Growth and New Product Rollouts

  1/31/2020

  Microbix Biosystems Inc. (TSX: MBX, Microbix®), a life sciences innovator making critical ingredients that enable the production of clinical diagnostics and creating medical devices that help ensure test accuracy, announces that it has completed a non-brokered private placement financing with gross proceeds of $2,355,000, by issuing an aggregate of 11,775,000 units (“Units”) at a price of $0.20 per Unit.

• Microbix Reports Results for Fiscal 2019Full-Year Sales of $13.4 Million, Progress Toward Sustained Profitability

  12/20/2019

  Microbix Biosystems Inc. (TSX: MBX, Microbix®), a life sciences innovator making critical ingredients that enable the production of clinical diagnostics and creating medical devices that help ensure test accuracy, reports results for its fiscal year (“2019”) and fourth quarter (“Q4”) ended September 30, 2019,

• Microbix Invited to Present Product Results at HPV CongressIVD Controls Data at EUROGIN, December 4-7, 2019

  12/2/2019

  Microbix Biosystems Inc. (TSX: MBX, Microbix®), a life sciences innovator making critical ingredients that enable the production of clinical diagnostics and creating medical devices that help ensure test accuracy, announces it has been invited to present the performance of its in-vitro diagnostics (IVD) quality products “IVD Controls” at EUROGIN 2019, the annual congress of the European Research Organization on Genital Infection & Neoplasia.

• Microbix Wins Ontario Business Award2019 “OBAA” for Excellence in Export Strategy

  11/18/2019

  Microbix Biosystems Inc. (TSX: MBX, Microbix®), a life sciences innovator making critical ingredients that enable the production of clinical diagnostics and creating medical devices (QAPs™) that help ensure test accuracy, announces it has been awarded the “Beyond Borders” Ontario Business Achievement Award (OBAA) for 2019 by the Ontario Chamber of Commerce (OCC).

• Microbix Presenting Product Results at Industry Conference

  10/8/2019

  Microbix Biosystems Inc. announces it is making two presentations about the performance of its in-vitro diagnostics quality products (IVD Controls) at the 11th European Meeting on Molecular Diagnostics (EMMD) in Noordwijk, The Netherlands, October 9-11, 2019.